CYP2D6*4 allele and breast cancer risk: Is there any association?

[1] Han W.(2004)Associations between breast cancer susceptibility gene polymorphisms and clinical pathological features Clin Cancer Res 10 124-139

[2] Kang D.(2005)Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome Mut Res 581 153-163

[3] Park I.A.(2006)Polymorphism in the CYP2D6 tamoxifen-metabolizing gene infl uences clinical effect but not hot fl ashes: data from the Italian Tamoxifen Trial J Clin Oncol 24 3708-3709

[4] Chacko P.(2009)Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales Pharmacogenet Genomics 9 170-179

[5] Joseph T.(2010)Intronic polymorphisms of cytochromes P450 Hum Genomics 4 402-405

[6] Mathew B.S.(2005)Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 6-13

[7] Bonanni B.(1999)A systematic review of genetic polymorphisms and breast cancer risk Cancer Epidemiol Biomarkers Prev 8 843-854

[8] Macis D.(2007)Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population Fundam Clin Pharmacol 21 419-426

[9] Maisonneuve P.(2008)Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population Cell Biochem Funct 26 76-81

[10] Sistonen J.(2007)CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure Pharmacogenet Genomics 17 93-101

[1] Han W.(2004)Associations between breast cancer susceptibility gene polymorphisms and clinical pathological features Clin Cancer Res 10 124-139

[2] Kang D.(2005)Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome Mut Res 581 153-163

[3] Park I.A.(2006)Polymorphism in the CYP2D6 tamoxifen-metabolizing gene infl uences clinical effect but not hot fl ashes: data from the Italian Tamoxifen Trial J Clin Oncol 24 3708-3709

[4] Chacko P.(2009)Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales Pharmacogenet Genomics 9 170-179

[5] Joseph T.(2010)Intronic polymorphisms of cytochromes P450 Hum Genomics 4 402-405

[6] Mathew B.S.(2005)Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity Pharmacogenomics J 5 6-13

[7] Bonanni B.(1999)A systematic review of genetic polymorphisms and breast cancer risk Cancer Epidemiol Biomarkers Prev 8 843-854

[8] Macis D.(2007)Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population Fundam Clin Pharmacol 21 419-426

[9] Maisonneuve P.(2008)Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population Cell Biochem Funct 26 76-81

[10] Sistonen J.(2007)CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure Pharmacogenet Genomics 17 93-101